Tabelecleucel
Tabelecleucel
Tabelecleucel (pronounced ta-bel-e-kloo-sel) is a type of immunotherapy used in the treatment of certain types of cancer. It is specifically designed for patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (PTLD) who have failed rituximab or rituximab and chemotherapy.
Etymology
The name "Tabelecleucel" is derived from the method of its production. "Tab" refers to the tabulation of the cells used in the therapy, "ele" is short for "element", referring to the basic building blocks of the therapy, and "cleucel" is a combination of "clonal" and "cell", referring to the clonal expansion of cells that is a key part of the therapy.
Mechanism of Action
Tabelecleucel works by introducing EBV-specific cytotoxic T lymphocytes (CTLs) into the patient's body. These CTLs are able to recognize and kill EBV-infected B cells, which are often the cause of PTLD.
Related Terms
- Immunotherapy: A type of treatment that uses the body's own immune system to fight disease.
- Epstein-Barr virus (EBV): A virus that can cause mononucleosis and is associated with certain types of cancer.
- Post-transplant lymphoproliferative disorder (PTLD): A condition that can occur after an organ transplant, where the immune system begins to attack the new organ.
- Rituximab: A type of drug used to treat certain types of cancer and autoimmune diseases.
- Chemotherapy: A type of cancer treatment that uses drugs to kill cancer cells.
External links
- Medical encyclopedia article on Tabelecleucel
- Wikipedia's article - Tabelecleucel
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski